Holen Sie sich die Stockscreener-App
472.80
1.91%
-9.23
Handel nachbörslich:
472.80
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TMO?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$482.03
Offen:
$484.22
24-Stunden-Volumen:
1.72M
Relative Volume:
0.77
Marktkapitalisierung:
$175.70B
Einnahmen:
$45.20B
Nettoeinkommen (Verlust:
$6.87B
KGV:
25.99
EPS:
18.1888
Netto-Cashflow:
$6.75B
1W Leistung:
-4.00%
1M Leistung:
+1.29%
6M Leistung:
-17.45%
1J Leistung:
+18.69%
1-Tages-Spanne:
$469.62
$486.79
1-Wochen-Bereich:
$469.11
$496.28
52-Wochen-Spanne:
$385.46
$643.99
Thermo Fisher Scientific Inc Stock (TMO) Company Profile
Firmenname
Thermo Fisher Scientific Inc
Sektor
Branche
Telefon
(781) 622-1000
Adresse
168 THIRD AVENUE, WALTHAM, MA
Compare TMO vs DHR, IDXX, A, WAT
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TMO
Thermo Fisher Scientific Inc
|
472.80 | 179.13B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
184.30 | 132.10B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
562.16 | 44.55B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
135.44 | 39.08B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
365.36 | 36.96B | 3.77B | 449.25M | 240.68M | 7.8556 |
Thermo Fisher Scientific Inc Stock (TMO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-27 | Eingeleitet | DZ Bank | Buy |
| 2025-12-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-12-09 | Eingeleitet | Goldman | Buy |
| 2025-12-08 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-12-01 | Hochstufung | HSBC Securities | Hold → Buy |
| 2025-09-11 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2025-08-19 | Eingeleitet | William Blair | Outperform |
| 2025-07-24 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-07-11 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2025-07-09 | Herabstufung | UBS | Buy → Neutral |
| 2025-01-10 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2024-12-23 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-10-14 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-10-01 | Eingeleitet | Stephens | Overweight |
| 2024-08-28 | Eingeleitet | Wells Fargo | Overweight |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-03-18 | Fortgesetzt | Citigroup | Neutral |
| 2024-01-24 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-01-08 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2023-12-18 | Eingeleitet | HSBC Securities | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-10-26 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-10-25 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2023-09-28 | Eingeleitet | Bernstein | Outperform |
| 2023-09-06 | Fortgesetzt | Citigroup | Buy |
| 2023-07-19 | Eingeleitet | Raymond James | Outperform |
| 2023-07-19 | Bestätigt | Robert W. Baird | Outperform |
| 2023-07-13 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2023-04-04 | Bestätigt | Barclays | Overweight |
| 2022-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-10-27 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2022-08-25 | Eingeleitet | Credit Suisse | Neutral |
| 2022-04-25 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2022-01-26 | Fortgesetzt | Barclays | Overweight |
| 2021-10-20 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-07-16 | Eingeleitet | The Benchmark Company | Buy |
| 2021-03-18 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-03-03 | Eingeleitet | Barclays | Overweight |
| 2021-01-08 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-12-02 | Eingeleitet | Goldman | Buy |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2020-09-30 | Eingeleitet | Atlantic Equities | Overweight |
| 2020-09-14 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-08-20 | Fortgesetzt | JP Morgan | Overweight |
| 2020-07-15 | Hochstufung | Cleveland Research | Neutral → Buy |
| 2020-07-07 | Bestätigt | Needham | Buy |
| 2020-04-23 | Bestätigt | Needham | Buy |
| 2020-01-31 | Bestätigt | Needham | Buy |
| 2020-01-22 | Eingeleitet | Credit Suisse | Neutral |
| 2020-01-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-11-15 | Eingeleitet | Stifel | Buy |
| 2019-07-25 | Bestätigt | Needham | Buy |
| 2019-07-16 | Herabstufung | Needham | Strong Buy → Buy |
| 2019-05-30 | Eingeleitet | Wolfe Research | Outperform |
| 2019-05-23 | Bestätigt | Needham | Strong Buy |
| 2019-04-22 | Bestätigt | Needham | Strong Buy |
| 2019-04-16 | Bestätigt | BofA/Merrill | Buy |
Alle ansehen
Thermo Fisher Scientific Inc Aktie (TMO) Neueste Nachrichten
Thermo Fisher Stock Price Target: What Analysts Say About TMO in 2026 - TIKR.com
Thermo Fisher Scientific Inc. stock falls Friday, still outperforms market - MarketWatch
Thermo Fisher Scientific Introduces Thermo Scientific Glacios 3 Cryo-TEM - Medical Product Outsourcing
Thermo Fisher Scientific introduces M Series Centrifuges to support flexible and sustainable workflows - Select Science
The Bull Case For Thermo Fisher Scientific (TMO) Could Change Following AI-Enhanced Orbitrap Drug Discovery Launches – Learn Why - Yahoo Finance
Thermo Fisher Scientific Inc. stock rises Thursday, outperforms market - MarketWatch
Thermo Fisher Introduces M Series Centrifuges - Contract Pharma
Thermo Fisher Scientific debuts Orbitrap and AI tools at ASMS 2026 - Select Science
Biophotonics Industry Set for Strong Growth by 2035 - SNS Insider
HSBC downgrades Thermo Fisher stock rating on growth concerns By Investing.com - Investing.com Canada
Thermo Fisher Scientific (TMO): Company Profile, Stock Price, News, Rankings - Fortune
Thermo Fisher Scientific Unveils Next-generation Innovations at ASMS 2026 to Accelerate Drug Discovery - BioSpectrum Asia
Thermo Fisher Scientific Inc. stock falls Tuesday, underperforms market - MarketWatch
Is Thermo Fisher Scientific stock underperforming the S&P 500? - MSN
Thermo Fisher Scientific Inc (TMO) Stock Price, Trades & News - GuruFocus
The Next Chapter for Orbitrap, Thermo Fisher’s ASMS 2026 Lineup - AIM Media House
Thermo Fisher Scientific Inc Stock (TMO) Moved Down by 3.01% on Jun 2: Key Drivers Unveiled - TradingKey
West Appoints Michel Lagarde a President and CEO - Contract Pharma
Mettler-Toledo International vs Thermo Fisher Scientific: Which Is the Stronger Buy Today? - Trefis
Is Thermo Fisher Scientific (TMO) Pricing Look Interesting After Recent Share Price Swings - Yahoo Finance
Thermo Fisher Scientific vs Mettler-Toledo International: Which Stock Could Rally? - Trefis
Thermo Fisher expands Orbitrap innovation across research, biopharma and applied testing - BioSpectrum Asia
The Zacks Analyst Blog Highlights Microsoft, Dell, Thermo Fisher,Village Super Market and Comstock - Yahoo Finance
Thermo Fisher Scientific Expands Orbitrap Innovation Across Research, Biopharma and Applied Testing at ASMS 2026 - BioSpace
Thermo Fisher Scientific introduces expanded Orbitrap solutions for research and applied sciences - BioSpectrum Asia
West Pharma names former Thermo Fisher executive Lagarde as CEO - WSAU
Wolfe Research initiates Thermo Fisher stock coverage with Outperform rating - Investing.com
Wolfe Research initiates Thermo Fisher stock coverage with Outperform rating By Investing.com - Investing.com Canada
Top Analyst Reports for Microsoft, Dell & Thermo Fisher - Yahoo Finance
Thermo Fisher Scientific (TMO) Stock Valuation Analysis Reveals Mixed Signals - GuruFocus
2 of Wall Street’s Favorite Stocks with Exciting Potential and 1 Facing Challenges - Yahoo Finance
Thermo Fisher Scientific Inc (TMO) Stock Analysis: Assessing a 24.17% Potential Upside and Strong Market Position - DirectorsTalk Interviews
Top analyst reports for Microsoft, Dell & Thermo Fisher - MSN
Thermo Fisher Unveils AI Orbitraps And Swedish Labs As Valuation Lags - Yahoo Finance
Thermo Fisher Scientific Stock: Why Analyst Consensus Is 27 Buys With Zero Sells - TIKR.com
Thermo Fisher Rose 10% This Week. Here’s What to Expect in 2026 - TIKR.com
Thermo Fisher Beats Black Worker’s Race, Sex Discrimination Suit - Bloomberg Law News
Thermo Fisher Scientific Hits Day High with 6.8% Intraday Surge - Markets Mojo
Thermo Fisher Scientific (TMO) Advances 1.56% as Stock Holds Above Key SupportGamma Squeeze - The Legal Advocate
Fidelity files Form 144: TMO proposed sale of 45,940 shares (05/29/2026) - Stock Titan
Is Thermo Fisher Scientific Stock Underperforming the S&P 500? - Yahoo Finance
Thermo Fisher (TMO) Surges 6.8%: Is This an Indication of Further Gains? - Yahoo Finance
Thermo Fisher Scientific Targets Seven Percent Long Term Organic Revenue Growth - HarianBasis.co
Thermo Fisher Scientific Inc (TMO) Stock Up 6.8% and Still Under - GuruFocus
Thermo Fisher Scientific Inc Stock (TMO) Moved Up by 5.14% on May 28: Drivers Behind the Movement - TradingKey
Thermo Fisher Launches E-Gel Power Snap Lite System - Contract Pharma
Thermo Fisher Scientific on Pace for Largest Percent Increase Since October 2025 — Data Talk - Morningstar
Thermo Fisher Scientific on Pace for Largest Percent Increase Since October 2025 -- Data Talk - Moomoo
Thermo Fisher (TMO) Unveils Advanced Mass Spectrometers at Key C - GuruFocus
Thermo Fisher Scientific Unveils Next-generation Innovations at ASMS 2026 to Accelerate the Path from Drug Discovery to New Therapies - BioSpace
New Thermo Fisher AI tools aim to speed drug discovery workflows - Stock Titan
Finanzdaten der Thermo Fisher Scientific Inc-Aktie (TMO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):